Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells

The multitargeted antifolate pemetrexed has demonstrated certain clinical activities against nonsmall cell lung cancer (NSCLC). Resveratrol (3,5,4-trihydroxy-trans-stilbene) is a polyphenol found in grapes and other plants and has great potential as a preventative and therapeutic agent due to its an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Naunyn-Schmiedeberg's archives of pharmacology 2013-12, Vol.386 (12), p.1047-1059
Hauptverfasser:	Chen, Ruey-Shyang, Ko, Jen-Chung, Chiu, Hsien-Chun, Wo, Ting-Yu, Huang, Yi-Jhen, Tseng, Sheng-Chieh, Chen, Huang-Jen, Huang, Yu-Ching, Jian, Yi-Jun, Lee, Wei-Ting, Lin, Yun-Wei
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Biomedical and Life Sciences Biomedicine Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Cell Survival - drug effects DNA Repair - drug effects DNA-Binding Proteins - metabolism Dose-Response Relationship, Drug Down-Regulation Endonucleases - metabolism Enzyme Activation Gene Expression Regulation, Enzymologic Gene Expression Regulation, Neoplastic Glutamates - pharmacology Guanine - analogs & derivatives Guanine - pharmacology Humans Lung Neoplasms - enzymology Lung Neoplasms - genetics Lung Neoplasms - pathology MAP Kinase Kinase 3 - metabolism MAP Kinase Kinase 6 - metabolism Neurosciences Original Article p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors p38 Mitogen-Activated Protein Kinases - metabolism Pemetrexed Pharmacology/Toxicology Protein Kinase Inhibitors - pharmacology RNA Interference RNA, Messenger - metabolism Signal Transduction - drug effects Stilbenes - pharmacology Time Factors Transfection
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!